<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DDI-DrugBank.d52">
    <sentence id="DDI-DrugBank.d52.s0" text="Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation">
        <entity charOffset="27-39" id="DDI-DrugBank.d52.s0.e0" text="thrombolytics" type="group"/>
        <entity charOffset="55-67" id="DDI-DrugBank.d52.s0.e1" text="streptokinase" type="drug"/>
        <entity charOffset="158-165" id="DDI-DrugBank.d52.s0.e2" text="REFLUDAN" type="brand"/>
        <pair ddi="false" e1="DDI-DrugBank.d52.s0.e0" e2="DDI-DrugBank.d52.s0.e1" id="DDI-DrugBank.d52.s0.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d52.s0.e0" e2="DDI-DrugBank.d52.s0.e2" id="DDI-DrugBank.d52.s0.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d52.s0.e1" e2="DDI-DrugBank.d52.s0.e2" id="DDI-DrugBank.d52.s0.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d52.s1" text="Concomitant treatment with coumarin derivatives (vitamin K antagonists) and drugs that affect platelet function may also increase the risk of bleeding.">
        <entity charOffset="27-46" id="DDI-DrugBank.d52.s1.e0" text="coumarin derivatives" type="group"/>
        <entity charOffset="49-69" id="DDI-DrugBank.d52.s1.e1" text="vitamin K antagonists" type="group"/>
        <pair ddi="false" e1="DDI-DrugBank.d52.s1.e0" e2="DDI-DrugBank.d52.s1.e1" id="DDI-DrugBank.d52.s1.p0"/>
    </sentence>
</document>